Gensight Biologics S.a annual r&d spending
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a R&D Spending Growth & History (SIGHT)
Gensight Biologics S.a's r&d spending was €6.4M for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €6.4M | −€5.9M | −47.93% |
| 2024 | 2024-12-31 | €12.4M | −€7.0M | −36.12% |
| 2023 | 2023-12-31 | €19.4M | €17,000 | +0.09% |
| 2022 | 2022-12-31 | €19.3M | −€3.6M | −15.61% |
| 2021 | 2021-12-31 | €22.9M | €534,000 | +2.39% |
| 2020 | 2020-12-31 | €22.4M | — | — |
Gensight Biologics S.a r&d spending trends
Over the last five fiscal years, Gensight Biologics S.a's r&d spending decreased from €22.4M to €6.4M, a change of −€15.9M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
reported R&D expense
TickerStat standardizes research and development expense reported in company official filings, including the software-specific standardized R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...